MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis

Medical Oncology

Volumn 31, Issue 6, 2014, Pages

  Zhang, Zhiyong ^a   Zheng, Wei ^a   Hai, Jun ^a  

^a SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; MiR 148b; Prognosis; Realtime PCR

Indexed keywords

MICRORNA; MICRORNA 148B; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; MIRN148 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETIC LINKAGE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; AGED; CARCINOMA, HEPATOCELLULAR; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REFERENCE VALUE; SURVIVAL RATE;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REFERENCE VALUES; SURVIVAL RATE;

EID: 84901727891     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0984-6     Document Type: Article

References (40)

1. Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013;14(8):535-48. doi:10.1038/nrg3471.
2. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350- 5. doi:10.1038/nature02871. (Pubitemid 39265675)
3. Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014;. doi:10.1038/bjc.2014.119.
4. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet. 2010;3(5):484-8. doi:10.1161/ CIRCGENETICS.110.958363.
5. Jin XF, Wu N, Wang L, Li J. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol. 2013;33(5):601-13. doi:10.1007/s10571-013-9940-9.
6. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics: a comprehensive review. EMBO Mol Med. 2012;4(3):143-59. doi:10.1002/emmm.201100209.
7. Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer. 2012;130(9):2077-87. doi:10.1002/ijc. 26232.
8. Xu Y, Li L, Xiang X, Wang H, Cai W, Xie J, et al. Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: a systematic review and meta-analysis. Gene. 2013;527(2):584-93. doi:10.1016/j.gene.2013.05.085.
9. Wang C, Ren R, Hu H, Tan C, Han M, Wang X et al (2014) MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma. Chin J Cancer Res = Chung-kuo yen cheng yen chiu. 26(1):17-29. doi:10.3978/j.issn.1000-9604.2014. 01.01.
10. Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG, Qin CK. Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol. 2014;9(1):47. doi:10.1186/1746-1596-9-47.
11. Zou C, Li Y, Cao Y, Zhang J, Jiang J, Sheng Y, et al. Upregulated MicroRNA-181a induces carcinogenesis in Hepatitis B virus-related hepatocellular carcinoma by targeting E2F5. BMC Cancer. 2014;14(1):97. doi:10.1186/1471-2407- 14-97.
12. Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One. 2014;9(2):e88393. doi:10.1371/journal.pone.0088393.
13. Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, et al. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol. 2010;53(1):98-107. doi:10.1016/j.jhep.2010.02.021.
14. Salvi A, Sabelli C, Moncini S, Venturin M, Arici B, Riva P, et al. MicroRNA-23b mediates urokinase and c-met down modulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J. 2009;276(11):2966-82. doi:10.1111/j.1742-4658.2009.07014.x.
15. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140(1):322-31. doi:10.1053/j.gastro.2010.10.006.
16. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69(3):1135-42. doi:10.1158/0008-5472.CAN-08- 2886.
17. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010;14(7):1170-9. doi:10.1007/s11605-010-1202-2.
18. Huang JJ, Yu J, Li JY, Liu YT, Zhong RQ. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol. 2012;29(4):2402-8. doi:10.1007/s12032-012-0210-3.
19. Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 2011;17(24):7574-83. doi:10.1158/1078-0432.CCR-11- 1714.
20. Yuan K, Lian Z, Sun B, Clayton MM, Ng IO, Feitelson MA. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One. 2012;7(4):e35331. doi:10.1371/journal.pone.0035331.
21. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virusrelated hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52(1):60-70. doi:10.1002/hep.23660.
22. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi:10.3322/caac.20107.
23. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. (Pubitemid 40372904)
24. Huang X, Hollinger FB. Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J Viral Hepat. 2014;21(3):153-62. doi:10.1111/jvh.12222.
25. Chan DL, Alzahrani NA, Morris DL, Chua TC. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(1):31-41. doi:10.1111/jgh.12399.
26. Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8(9):e61361. doi:10.1371/journal.pone.0061361.
27. Ren W, Qi X, Jia J, Yang M, Han G. Prevalence of hepatocellular carcinoma in Chinese Budd-Chiari syndrome patients: an extended systematic review using Chinese-language databases. Eur J Gastroenterol Hepatol. 2013;25(10):1241-3. doi:10.1097/MEG.0b013e32836104a4.
28. Shen A, Zhang H, Tang C, Chen Y, Wang Y, Zhang C, et al. Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol. 2013;28(5):793-800. doi:10.1111/jgh.12162.
29. Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, et al. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma: systematic review and metaanalysis. Cancer Med. 2013;2(6):862-71. doi:10.1002/cam4.150.
30. Yin Z, Fan X, Ye H, Yin D, Wang J. Short- and long-term outcomes after laparoscopic and open hepatectomy for hepatocellular carcinoma: a global systematic review and meta-analysis. Ann Surg Oncol. 2013;20(4):1203-15. doi:10.1245/s10434-012-2705-8.
31. Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Vigano R, Cordone G, et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol. 2013;25(2):180-6. doi:10.1097/MEG.0b013e328359e550.
32. Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38(4):286-95. doi:10.1016/j.ejso.2012.01.006.
33. Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20(1):325-39. doi:10.1245/s10434-012-2513-1.
34. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861-74. doi:10.1038/nrg3074.
35. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522-31. doi:10.1038/nrg1379. (Pubitemid 38868508)
36. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005;4(9):1179-84. (Pubitemid 41365387)
37. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11(12):849-64. doi:10.1038/nrc3166.
38. Zhao Y, Jia HL, Zhou HJ, Dong QZ, Fu LY, Yan ZW, et al. [Identification of metastasis-related microRNAs of hepatocellular carcinoma in hepatocellular carcinoma cell lines by quantitative real time PCR]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi =. Chin J Hepatol. 2009;17(7):526-30.
39. Song Y, Xu Y, Wang Z, Chen Y, Yue Z, Gao P, et al. MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int J Cancer. 2012;131(5):1042-51. doi:10.1002/ijc.26485.
40. Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM, et al. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer. 2011;10:1. doi:10.1186/1476-4598-10- 1.